Physician profile
Michael Milliken
NPI 1629275037
$5,147.48
in general payments reported to CMS, 2019-2025
21 companies · $499 in 2025
The $499 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2021: $380 · 2022: $859 · 2023: $2,359 · 2024: $518 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,005 · Consulting Fee: $1,180 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,005.11 |
| Consulting Fee | $1,180.00 |
| Education | $190.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,340.18 | 2021-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $1,251.97 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $337.51 | 2022-2025 | Sotyktu |
| Amgen INC. | $336.51 | 2021-2024 | Otezla |
| Janssen Biotech, INC. | $324.29 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $204.89 | 2021-2025 | |
| Genzyme Corporation | $193.71 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $188.78 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $131.78 | 2022-2024 | Taltz, Olumiant |
| Pfizer INC. | $111.19 | 2021-2025 | |
| Incyte Corporation | $107.40 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $104.19 | 2023 | Adbry |
| Sun Pharmaceutical Industries INC. | $102.55 | 2023-2024 | Ilumya |
| Sanofi-Aventis U.S. LLC | $99.03 | 2019 | |
| Boston Scientific Corporation | $90.58 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $70.79 | 2021-2024 | Poteligeo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.43 | 2023-2024 | Cyltezo, Spevigo |
| Arcutis Biotherapeutics, INC. | $50.44 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.03 | 2025 | Cabtreo |
| Genentech USA, INC. | $15.78 | 2023 | Xolair |
| Galderma Laboratories, L.P. | $12.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Milliken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.